title: Adapting the GLP-1-signaling system to the treatment of type 2 diabetes.
abstract: Glucagon-like peptide-1 (GLP-1) may contribute to the decreased incretin effect characterizing type 2 diabetes. Multiple actions other than insulin secretion stimulation give to GLP-1 a highly desirable profile for an antidiabetic agent. To overcome the need for continuous infusion of the native compound, which is rapidly degraded by dimethyl-peptidyl-peptidase-IV (DPP-IV), analogues with low affinity for this protease have been developed. A second major strategy is represented by DPP-IV inhibitors that act to increase endogenous GLP-1. On the basis of the promising results in clinical trials, the incretin-based therapy may offer an useful option for diabetes management.
authors.affiliation: Department of Clinical and Experimental Medicine "Lanzara-Magrassi", Second University of Naples, Italy. teresa.salvatore@unina2.it
authors.forename: Teresa
authors.initials: T
authors.lastname: Salvatore
authors.forename: Ornella
authors.initials: O
authors.lastname: Carbonara
authors.forename: Domenico
authors.initials: D
authors.lastname: Cozzolino
authors.forename: Roberto
authors.initials: R
authors.lastname: Torella
authors.forename: Ferdinando Carlo
authors.initials: FC
authors.lastname: Sasso
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D016503:Drug Delivery Systems; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005749:Gastric Inhibitory Polypeptide / Q000502:physiology; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000378:metabolism / Q000502:physiology / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D054795:Incretins / Q000494:pharmacology; D000069450:Liraglutide; D008301:Maleimides / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D011499:Protein Processing, Post-Translational; D015398:Signal Transduction / Q000187:drug effects
chemical_list: C473712:CJC 1131; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D054795:Incretins; D008301:Maleimides; D010455:Peptides; D005749:Gastric Inhibitory Polypeptide; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4